将STING激活与编程死亡连接体1抑制集成:癌症治疗的新方法
Hossein Khorramdelazad1, Reyhaneh Arfaei2, Pegah Yaraghi3
1Molecular Medicine Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Science, Rafsanjan, Iran; Department of Immunology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Critical reviews in oncology/hematology
|February 18, 2026
概括
免疫检查点抑制剂 (ICI) 与STING激动剂相结合,在癌症治疗中表现有前途,但面临挑战. 新型药物输送和生物标志物对于优化STING/ICI组合策略以获得更好的患者结果至关重要.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 免疫检查点抑制剂 (ICI) 已经彻底改变了癌症治疗,但耐药性和可变的结果仍然存在.
- 干扰素基因刺激器 (STING) 途径是癌症免疫反应的关键调节者,在瘤微环境中具有复杂的作用.
- 了解STING激活的双重作用对于其在癌症免疫治疗中的治疗应用至关重要.
研究的目的:
- 批判性地评估将STING激动剂与PD-1/PD-L1抑制剂相结合的治疗潜力和风险.
- 综合STING/ICI组合策略的机理学,翻译和临床证据.
- 探索新的药物输送平台和生物标志物引导的方法,以优化癌症免疫治疗.
主要方法:
- 对STING激动剂和PD-1/PD-L1抑制剂的临床前研究的综述.
- 对STING激动剂的早期临床试验数据的分析.
- 关于癌症免疫治疗药物输送系统和生物标志物的证据综合.
主要成果:
- 临床前数据表明,STING/ICI组合可以增强抗瘤免疫力.
- 早期临床试验显示安全性和途径参与,但反应适度和变化.
- 挑战包括初级耐药性,有限的耐久性和异质的临床结果.
结论:
- STING/PD-1/PD-L1组合策略具有治疗前景,但需要仔细优化.
- 新兴的药物输送平台和以生物标志物为指导的方法对于提高疗效和安全至关重要.
- 需要进一步的研究来推进基于STING的免疫疗法,以实现持久和个性化的癌症治疗.
相关概念视频
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
02:50Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
01:31The Intrinsic Apoptotic Pathway
8.8K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.8K
01:27Tumor Immunotherapy
2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
01:17The Extrinsic Apoptotic Pathway
8.9K
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
8.9K